Research programme: Bardet-biedl syndrome therapeutics - Rescindo Therapeutics
Latest Information Update: 12 Apr 2022
At a glance
- Originator Rescindo Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bardet-Biedl Syndrome
Most Recent Events
- 05 Apr 2022 Preclinical trials in Bardet-Biedl Syndrome in USA (unspecified route) (Rescindo Therapeutics pipeline, March 2022)